Gastrointestinal (GI) NETs

PRRT Trials

• Alpha PRRT with Pb-212 (all NET)

• Alpha PRRT with Ac-225 (GEP-NETs only)

• Lu-177 DOTATATE + M3814 (Peposertib)  (GEP-NETs)

• Lu-177 DOTATATE + Olaparib  (GEP-NETs)

• Lu-177 DOTATATE + Triapine (GEP-NETs)

• Lu-177 DOTATATE + Cabozantanib (all NET)

• COMPOSE (GEP-NETS)

• NETTER-P: Lutathera in Adolescent Patients 

• NET RETREAT of Lu-177 Retreatment vs Everolimus in Midgut NET

Oral Treatment

• CABINET: Cabozantinib in Advanced pNET and Carcinoid Tumors

• CDK4/6 Abemaciclib

SSA Treatments

• Paltusotine in Carcinoid Syndrome 

• SORENTO™: Subcutaneous Octreotide for GEP-NETs

Other Trials

• Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

• Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs

• Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs)